Sign in
ANEB Stock Price, Chart, Stats & News
Anebulo Pharmaceuticals Inc
Save
Anebulo Pharmaceuticals Inc (ANEB) does not currently pay a dividend.
–
Market cap
–
Current P/E
–
Forward P/E
ANEB chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -84.68% |
ROE | -74.58% |
D/E | – |
Interest coverage ratio | -30.60x |
ANEB valuation
P/E | – |
P/S | – |
P/B | 4.59x |
P/CF | -6.24x |
P/FCF | -6.19x |
P/OCF | -6.24x |
PEG | -0.22x |
EV multiple | -5.44x |
About
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company’s lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Lakeway, Texas.
Similar securities
Based on sector and market capitalization
Report issue